Myelodysplastic syndromes

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 6, Issue 9, 2008, Pages 902-925

  Greenberg, Peter L ^a   Attar, Eyal ^a   Battiwalla, Minoo ^a   Bennett, John M ^a   Bloomfield, Clara D ^a   DeCastro, Carlos M ^a   Deeg, Joachim ^a   Erba, Harry P ^a   Foran, James M ^a   Garcia Manero, Guillermo ^a   Gore, Steven D ^a   Head, David ^a   Maness, Lori J ^a   Millenson, Michael ^a   Nimer, Stephen D ^a   O'Donnell, Margaret R ^a   Saba, Hussain I ^a   Shami, Paul J ^a   Spiers, Kathy ^a   Stone, Richard M ^a   Tallman, Martin S ^a   Westervelt, Peter ^a   more..

^a NONE

Author keywords

Chronic myelomonocytic leukemia; Cytopenias; Myelodysplastic syndromes; NCCN clinical practice guidelines; Refractory anemia; Treatment

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AMINOCAPROIC ACID; ANTIBIOTIC AGENT; ANTIFIBRINOLYTIC AGENT; ANTINEOPLASTIC AGENT; AZACITIDINE; CYCLOSPORIN; CYCLOSPORIN A; DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; DNA METHYLTRANSFERASE INHIBITOR; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOSUPPRESSIVE AGENT; LENALIDOMIDE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; THALIDOMIDE; THYMOCYTE ANTIBODY; TUMOR NECROSIS FACTOR ANTIBODY; VITAMIN D DERIVATIVE;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOTRANSPLANTATION; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BACTERIAL INFECTION; BLEEDING; BLOOD CELL COUNT; BLOOD SMEAR; BONE MARROW BIOPSY; CANCER CLASSIFICATION; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CYTOGENETICS; CYTOPENIA; DISEASE COURSE; DISEASE SEVERITY; DOSAGE SCHEDULE COMPARISON; DRUG DOSE REDUCTION; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; ERYTHROCYTE TRANSFUSION; FANCONI ANEMIA; FOLLOW UP; HISTOPATHOLOGY; HLA TYPING; HUMAN; IRON OVERLOAD; LABORATORY TEST; LOW DRUG DOSE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MYELOABLATIVE CONDITIONING; MYELODYSPLASIA; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; ONCOLOGY; OUTCOME ASSESSMENT; PATIENT MONITORING; PRACTICE GUIDELINE; PROGNOSIS; PSYCHOSOCIAL CARE; QUALITY OF LIFE; REFRACTORY ANEMIA; REFRACTORY ANEMIA WITH EXCESS BLASTS; REFRACTORY ANEMIA WITH EXCESS BLASTS IN TRANSFORMATION; REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS; REVIEW; SURVIVAL TIME; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; WORLD HEALTH ORGANIZATION;

EID: 56049098183     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2008.0069     Document Type: Review

References (110)

1. Greenberg PL. The myelodysplastic syndromes. In: Hoffman R, Benz E, Shattil S, et al., eds. Hematology: Basic Principles and Practice, 3rd ed. New York. Churchill Livingstone; 2000:1106-1129.
2. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982;51:189-199.
3. Kouides P, Bennett J. Morphology and classification of the myelodysplastic syndromes and their pathologic variants. Semin Hematol 1996;33:95-110.
4. Brunning R, Bennett J, Flandrin G, et al. Myelodysplastic syndromes. In: Jaffe F, Harris N, Stein H, et al., eds. WHO Classification of Tumours. Pathology and Genetics of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press; 2001;61-73.
5. Harris N, Jaffe E, Diebold J, et al. WHO classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999;17:3835-3849.
6. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002;100:2292-2302.
7. Kaloutsi V, Kohlmeyer U, Maschek H, et al. Comparison of bone marrow and hematologic findings in patients with human immunodeficiency virus infection and those with myelodysplastic syndromes and infectious diseases. Am J Clin Pathol 1994;101:123-129.
8. Greenberg P, Cox C, Le Beau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079-2088.
9. Greenberg P, Cox C, Le Beau MM, et al. Erratum: International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1998;91:1100.
10. List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006;355:1456-1465.
11. Greenberg P, Anderson J, De Witte T, et al. Problematic WHO reclassification of myelodysplastic syndromes. J Clin Oncol 2000;18: 3447-3449.
12. Albitar M, Manshouri T, Shen Y, et al. Myelodysplastic syndrome is not merely "preleukemia". Blood 2002;100:791-798.
13. Germing U, Gattermann N, Strupp C, et al. Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients. Leuk Res 2000;24:983-992.
14. Nosslinger T, Reisner R, Koller E, et al. Myelodysplastic syndromes, from French-American-British to World Health Organization: comparison of classifications on 431 unselected patients from a single institution. Blood 2001;98:2935-2941.
15. Arber DA, Porwit A, Brunning RD, et al. Acute myeloid leukaemia with myelodysplasia-related changes. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues, 4th ed. Lyon: IARC Press; in press.
16. Valent P, Horny HP, Bennett JM, et al. Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: consensus statements and report from a working conference. Leuk Res 2007;31:727-736.
17. Dunn DE, Tanawattanacharoen P, Boccuni P, et al. Paroxysmal nocturnal hemoglobinuria cells in patients with bone marrow failure syndromes. Ann Intern Med 1999;131:401-408.
18. Saunthararajah Y, Nakamura R, Nam JM et al. HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome. Blood 2002;100:1570-1574.
19. Baxter EJ, Kulkarni S, Vizmanos JL, et al. Novel translocations that disrupt the platelet-derived growth factor receptor beta (PDGFRB) gene in BCR-ABL-negative chronic myeloproliferative disorders. Br J Haematol 2003;120:251-256.
20. Steer EJ, Cross NC. Myeloproliferative disorders with translocations of chromosome 5q31-35: role of the platelet-derived growth factor receptor beta. Acta Haematol 2002;107:113-122.
21. Magnusson MK, Meade L, Nakamura R, et al. Activity of STI571 in chronic myelomonocytic leukemia with a platelet-derived growth factor beta receptor fusion oncogene. Blood 2002;100:1088-1091.
22. Apperley JF, Gardembas M, Melo JV, et al. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med 2002;347:481-487.
23. Steensma DP, Dewald GW, Lasho TL, et al. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes. Blood 2005;106:1207-1209.
24. Szpurka H, Tiu R, Murugesan G, et al, Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation. Blood 2006;108:2173-2181.
25. Ogata, K, Nakamura K, Yokose N, et al. Clinical significance of phenotypic features of blasts in patients with myelodysplastic syndrome. Blood 2002;100:3887-3896.
26. Wells DA, Benesch M, Loken MR, et al. Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hematopoietic stem cell transplantation. Blood 2003;102:394-403.
27. Sanz G, Sanz M, Greenberg P. Prognostic factors and scoring systems in myelodysplastic syndromes: recent advances in myelodysplastic syndromes. Haematologica 1998;83:358-368.
28. Bennett JM, Catovsky D, Daniel MT, et al. The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia. Proposals by the French-American-British Cooperative Leukaemia Group. Br J Haematol 1994;87:746-750.
29. Malcovati L, Della Porta MG, Pascutto C, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol 2005;23:7594-7603.
30. Kao JM, McMillan A, Greenberg PL. International MDS risk analysis workshop (IMRAW)/IPSS reanalyzed: impact of cytopenias on clinical outcomes in myelodysplastic syndromes. Am J Hematol 2008; in press.
31. Greenberg PL, Baer M, Bennett J, et al. NCCN Clinical Practice Guidelines in Oncology: Myelodysplastic Syndromes, Version 1, June 2001. Rockledge, PA: National Comprehensive Cancer Network. To view the most recent version of this NCCN guideline, go to www.nccn.org.
32. Cheson BD, Bennett JM, Kantarjian H, et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 2000;96:3671-3674.
33. Olivieri N, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood 1997;89:739-761.
34. Greenberg PL. Myelodysplastic syndromes: iron overload consequences and current chelating therapies. J Natl Compr Cancer Netw 2006;4:91-96.
35. Hershko C, Link G, Cabantchik I. Pathophysiology of iron overload. Ann NY Acad Sci 1998;850:191-201.
36. Farquhar MJ, Bowen DT. Oxidative stress and the myelodysplastic syndromes. Int J Hematol 2003;77:342-350.
37. Jensen PD, Heickendorff L, Pedersen B, et al. The effect of iron chelation on haemopoiesis in MDS patients with transfusional iron overload. Br J Haematol 1996;94:288-299.
38. Jensen PD, Jensen FF, Christensen T, et al. Evaluation of myocardial iron by magnetic resonance imaging during iron chelation therapy with deferrioxamine: indication of close relation between myocardial iron content and chelatable iron pool. Blood 2003;101: 4632-4639.
39. Malcovati L, Porta MG, Pascutto C, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol 2005;23:7594-7603.
40. Brittenham GM, Badman DG. Noninvasive measurement of iron: report of an NIDDK workshop. Blood 2003;101:15-19.
41. St Pierre T, Clark P, Chua-anusorn W, et al. Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood 2005;105:855-861.
42. Cohen AR, Galanello R, Piga A, et al. Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. Blood 2003;102:1583-1587.
43. Nisbet-Brown E, Olivieri NF, Giardina PJ, et al. Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 2003;361:1597-1602.
44. Piga A, Galanello R, Cappellini MD, et al. Phase II study of oral chelator ICL670 in thalassaemia patients with transfusional iron overload: efficacy, safety, pharmacokinetics and pharmacodynamics after 6 months of therapy [abstract]. Blood 2002;100: Abstract 5a.
45. Olivieri NF, Koren G, Hermann C, et al. Comparison of oral iron chelator L1 and desferrioxamine in iron-loaded patients. Lancet 1990;336:1275-1279.
46. Greenberg PL. The role of hemopoietic growth factors in the treatment of myelodysplastic syndromes. Int J Ped Hem-One 1997;4:231-238.
47. Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the CALGB. J Clin Oncol 2002;20: 2429-2440.
48. Kantarjian H, Issa JP, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006;106:1794-1803.
49. Silverman LR, McKenzie DR, Peterson BL, et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol 2006;24:3895-3903.
50. Fenaux P, Mufti GT, Santini V, et al, Azacitidine treatment prolongs overall survival in higher-risk MDS patients compared with conventional care regimens: results of the AZA-001 phase III study [abstract]. Blood 2007;110:Abstract 817.
51. Wijermans P, Lubbert M, Verhoef G, et al. Low-dose 5-aza-2′-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J Clin Oncol 2000;18:956-962.
52. Lubbert M, Wijermans P, Kunzmann R et al. Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2′-deoxycytidine. Br J Haematol 2001;14:349-357.
53. Saba H, Rosenfeld C, Issa JP, et al. First report of the phase III North American trial of decitabine in advanced myelodysplastic syndrome [abstract]. Blood 2004;104:Abstract 23a
54. Van den Bosch J, Lubbert M, Verhoef G, Wijermans PW. The effects of 5-aza-2′-deoxycytidine (decitabine) on the platelet count in patients with intermediate and high-risk myelodysplastic syndromes. Leuk Res 2004;28:785-790.
55. Saba H, Lübbert M, Wijermans P. Response rates of phase 2 and phase 3 trials of decitabine (DAC) in patients with myelodysplastic syndromes (MDS) [abstract]. Blood 2005;106:Abstract 706a.
56. Kantarjian H, O'Brien S, Giles F, et al. Decitabine low-dose schedule (100 mg/m2/course) in myelodysplastic syndrome (MDS). Comparison of 3 different dose schedules [abstract]. Blood 2005;106:Abstract 708a.
57. Kantarjian HM, O'Brien S, Shan J, et al. Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome. Cancer 2007;15;109: 265-273.
58. Kantarjian H, Oki Y, Garcia-Manero G, et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 2007;109:52-57.
59. Jonasova A, Neuwirtova R, Cermak J, et al. Promising cyclosporin A therapy for myelodysplastic syndrome. Leuk Res 1997;21:S42.
60. Molldrem J, Caples M, Mavroudis D, et al. Antithymocyte globulin for patients with myelodysplastic syndromes. Br J Haematol 1997;99:699-705.
61. Raza A, Meyer P, Dutt D, et al. Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. Blood 2001;98:958-965.
62. Strupp C, Germing U, Aivado M, et al. Thalidomide for the treatment of patients with myelodysplastic syndromes. Leukemia 2002;6:1-6.
63. Deeg HJ, Gotlib J, Beckham C, et al. Soluble TNF receptor fusion protein (etanercept) for the treatment of myelodysplastic syndrome. Leukemia 2002;16:162-164.
64. Deeg HJ, Jiang PYZ, Holmberg LA, et al. Hematologic responses of patients with MDS to antithymocyte globulin plus etanercept correlate with improved flow scores of marrow cells. Leuk Res 2004;28: 1177-1180.
65. List A, Dewald G, Bennett J, et al. Hematologic and cytogenetic response to lenalidomide in myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006;355:1456-1465.
66. Sloand EM, Wu C, Greenberg P, et al. Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy. J Clin Oncol 2008;26:2505-2511.
67. List A, Kurtin S, Roe DJ, et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 2005;352:549-557.
68. Nimer SD. Clinical management of myelodysplastic syndromes with interstitial deletion of chromosome 5q. J Clin Oncol 2006; 24:2576-2582.
69. Raza A, Reeves JA, Feldman EJ, et al. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1-risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood 2008;111:86-93.
70. Tricot G, Boogaerts MA. The role of aggressive chemotherapy in the treatment of myelodysplastic syndromes. Br J Haematol 1986; 63:477-483.
71. Estey EH, Thall PF, Cortes JE, et al. Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts. Blood 2001;98:3575-3583.
72. Sonneveld P, Van Dongen J, Hagemeijet A, et al. High expression of MDR-1 in marrow cells from patients with myelodysplastic syndrome. Leukemia 1993;7:963-969.
73. Wattel E, Solary E, Caillot D, et al. Quinine improves results of intensive chemotherapy in myelodysplastic syndromes expressing P-glycoprotein. Adv Exp Med Biol 1995;457:35-46.
74. Advani R, Saba H, Tallman M, et al. Treatment of relapsed/refractory AML with combination chemotherapy plus the multi-drug resistance modulator PSC833. Blood 1999;93:787-795.
75. Greenberg P, Lee S, Advani R, et al. Mitoxantrone, etoposide and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995). J Clin Oncol 2004;22: 1078-1086.
76. Anderson JE, Appelbaum FR, Fisher L, et al. Allogeneic bone marrow transplantation for 93 patients with myelodysplastic syndrome. Blood 1993;82:677-681.
77. Anderson JE, Thomas ED. The Seattle experience with bone marrow transplantation for MDS. Leuk Res 1997;21 (Suppl 1):S51.
78. Scott BL, Sandmaier BM, Storer B, et al. Myeloablative vs non-myeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis. Leukemia 2006;20:128-135.
79. Kerbauy DMB, Chyou F, Gooley T, et al. Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia. Biol Blood Marrow Transplant 2005;11:713-720.
80. Wallen H, Gooley TA, Deeg HJ, et al. Ablative allogeneic hematopoietic cell transplantation in adults 60 years of age and older. J Clin Oncol 2005;23:3439-3446.
81. Nevill TJ, Fung HC, Shepherd JD, et al. Cytogenetic abnormalities in primary myelodysplastic syndrome are highly predictive of outcome after allogeneic bone marrow transplantation. Blood 1998;92:1910-1917.
82. Jurado M, Deeg HJ, Storer B, et al. Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome after conditioning with busulfan and fractionated total body irradiation is associated with low relapse rate but considerable nonrelapse mortality. Biol Blood Marrow Transplant 2002;8:161-169.
83. De Witte T, Zwaan F, Hermans J, et al. Allogeneic bone marrow transplantation for secondary leukaemia and myelodysplastic syndrome: a survey by the Leukaemia Working Party of the European Bone Marrow Transplantation Group (EBMTG). Br J Haematol 1990;74:151-155.
84. Demuynck H, Verhoef GE, Zachee P, et al. Treatment of patients with MDS with allogeneic bone marrow transplantation from genotypically similar HLA-identical sibling and alternative donors. Bone Marrow Transplant 1996;17:745-751.
85. Giralt S, Esrey E, Albitar M, et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus leukemia without myeloablative therapy. Blood 1997;89:4531-4536.
86. De Lima M, Anagnostopoulos A, Munsell M, et al. Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. Blood 2004; 104:865-872.
87. Anderson JE, Anasetti C, Appelbaum FR. Unrelated donor marrow transplantation for myelodysplasia and MDS-related acute myeloid leukaemia. Br J Haematol 1996;93:59-67.
88. Deeg HJ. Optimization of transplant regimens for patients with myelodysplastic syndromes (MDS). In: Hematology 2005: American Society of Hematology Education Program Book. Washington, DC: American Society of Hematology; 2005:167-173.
89. Castro-Malaspina H, Harris RE, Gajewski J, et al. Unrelated donor marrow transplantation for myelodysplastic syndromes: outcome analysis in 510 transplants facilitated by the National Marrow Donor Program. Blood 2002;99:1943-1951.
90. De Witte T, Suciu S, Verhoef G, et al. Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes and acute myeloid leukemia following MDS. Blood 2001;98:2326-2331.
91. Fukumoto JS, Greenberg PL. Management of patients with higher risk myelodysplastic syndromes. Crit Rev Oncol Hematol 2005;56: 179-192.
92. Cutler C, Lee SJ, Greenberg P, et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low risk myelodysplasia is associated with improved outcome. Blood 2004;104:579-585.
93. Beran M, Shen Y, Kantarjian H, et al. High-dose chemotherapy in high-risk myelodysplastic syndrome: covariate-adjusted comparison of five regimens. Cancer 2001;92:1999-2015.
94. Jacobs A, Janowska-Wieczorek A, Caro J, et al. Circulating erythropoietin in patients with myelodysplastic syndromes. Br J Haematol 1989;73-36-39.
95. Hellstrom-Lindberg E. Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies. Br J Haematol 1995;89:67-71.
96. Negrin RS, Stein R, Doherty K, et al. Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human G-CSF plus erythropoietin: evidence for in vivo synergy. Blood 1996;87:4076-4081.
97. Casadevall N, Durieux P, Dubois S, et al. Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial. Blood 2004;104: 321-327.
98. Hellstrom-Lindberg E, Ahlgren T, Beggumi Y, et al. Treatment of the anemia of myelodysplastic syndromes with G-CSF plus erythropoietin: results from a randomized phase II study and long term follow-up on 71 patients. Blood 1998;92:68-75.
99. Hellstrom-Lindberg E, Negrin R, Stein R, et al. Erythroid response to treatment with G-CSF plus erythropoietin for the anemia of patients with myelodysplastic syndromes: proposal for a predictive model. Br J Haematol 1997;99:344-351.
100. Spiriti MA, Latagliata R, Niscola P, et al. Impact of a new dosing regimen of epoetin alfa on quality of life and anemia in patients with low-risk myelodysplastic syndrome. Ann Hematol 2005;84:167-176.
101. Hellstom-Lindberg E, Guldbrandsen N, Lindberg G, et al. A validated decision model for treating MDS with erythropoietin and GCSF: significant effects on quality of life. Br J Haematol 2003;120: 1037-1046.
102. Musto P, Lanza F, Balleari E, et al. Darbepoetin alpha for the treatment of anaemia in low-intermediate risk myelodysplastic syndromes. Br J Haematol 2005;128:204-209.
103. Mannone L, Gardin C, Quarre MC, et al. High-dose darbepoetin alpha in the treatment of anaemia of lower risk myelodysplastic syndrome: results of a phase II study. Br J Haematol 2006;133:513-519.
104. Stasi R, Abruzzese E, Lanzetta G, et al. Darbepoetin alfa for the treatment of anemic patients with low- and intermodiate-1-risk myelodysplastic syndromes. Ann Oncol 2005;16:1921-1927.
105. Giraldo P, Nomdedeu B, Loscertales J, et al. Darbepoetin alpha for the treatment of anemia in patients with myelodysplastic syndromes. Cancer 2006;107:2807-2816.
106. Miller KB, Kim HT, Greenberg P, et al. Phase III prospective randomized trial of EPO with or without G-CSF versus supportive therapy alone in the treatment of myelodysplastic syndromes (MDS): results of the ECOG-CLSG trial (E1996) [abstract]. Blood 2004;104:Abstract 24a.
107. Jadersten M, Malcovati L, Dybedal I, et al. Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome. J Clin Oncol 2008;26:3607-3613.
108. Park S, Grabar S, Kelaidi C, et al. Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. Blood 2008;111:574-582.
109. Komblith AB, Herndon JE, Silverman LR, et al. Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a CALGB Study. J Clin Oncol 2002;20:2441-2452.
110. Thomas ML. Health-related quality of life for those with myelodysplastic syndrome: conceptualization, measurement and implications. In: Greenberg PL, ed. Myelodysplastic Syndromes: Clinical and Biological Advances. Cambridge: Cambridge University Press; 2006:263-295.